Donald L. Traul, Ph.D. joined AspenBio Pharma, Inc. (the predecessor of Riot) in May 2006. As of the October 2009 proxy, Dr. Traul served as Director of Scientific Projects. The compensation tables list the title as Manager-Scientific Projects. The company listed Dr. Traul as a significant employee and one of its most highly compensated employees, but did not treat the position as an "officer" under Exchange Act Rule 16a-1. Dr. Traul was therefore not a named executive officer.
Before AspenBio, Dr. Traul was a microbiologist with the USDA's Animal Disease Research Unit. Earlier, Dr. Traul was a research and development scientist at ThermoBioStar, developing immunologic and nucleic acid-based diagnostics. The filing gives no dates for these roles. Research areas include anti-cancer therapies, immunology, gene expression, molecular neurovirology, and pathogenesis of viruses and bacteria in animals. Dr. Traul holds a B.A. in Biology from St. Olaf College, a Master of Clinical Laboratory Sciences from the University of Wisconsin-Milwaukee, and a Ph.D. in Microbiology from Colorado State University. The proxy discloses no outside board seats.
Compensation: - 2008: $105,000 salary, $15,000 cash bonus (paid in 2009), $15,800 in option awards and $9,078 in group medical coverage, for a total of $144,878. - 2007: $90,000 salary, $40,000 bonus and $91,503 in option awards, for a total of $229,678. - At fiscal year-end 2008, Dr. Traul held 10,000 exercisable and 10,000 unexercisable options at $1.97, expiring November 21, 2016. - On January 27, 2009, Dr. Traul received a further 30,000 options at $1.69, vesting annually in arrears over three years with a ten-year term.
Biography extracted from Riot DEF 14A filed 2009-10-16 View cached copy (2026-09-27)Live source ↗
Compensation
| Year | Role as filed | Salary | Bonus | Option awards | Other | Total | Source |
|---|---|---|---|---|---|---|---|
| 2008 | — | $105.0K | $15.0K | $15.8K | $9.1K | $144.9K | View cached copy (2026-09-27)Live source ↗ |
As reported in the company's DEF 14A Summary Compensation Table (SEC Reg S-K Item 402(c)). Stock and option awards are grant-date fair values — what the award was worth on the day it was granted, not cash received and not what it is worth now. Every row here reconciles: its columns add up to the total the filing printed.